Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. Efficace F, et al. Among authors: rossi ar. Br J Cancer. 2012 Sep 4;107(6):904-9. doi: 10.1038/bjc.2012.348. Epub 2012 Aug 7. Br J Cancer. 2012. PMID: 22871884 Free PMC article.
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Efficace F, et al. Among authors: rossi ar. Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. Blood. 2011. PMID: 21750313 Free article.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, Crisà E, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G. Breccia M, et al. Among authors: rossi ar. Leuk Res. 2014 Oct;38(10):1173-6. doi: 10.1016/j.leukres.2014.06.020. Epub 2014 Jul 7. Leuk Res. 2014. PMID: 25047978
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Iurlo A, et al. Among authors: rossi ar. Oncotarget. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657. Oncotarget. 2016. PMID: 27579540 Free PMC article.
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G. Latagliata R, et al. Among authors: rossi ar. Leuk Res. 2011 Sep;35(9):1164-9. doi: 10.1016/j.leukres.2011.05.015. Epub 2011 Jun 25. Leuk Res. 2011. PMID: 21705080
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G. Breccia M, et al. Among authors: rossi ar. Am J Hematol. 2011 Jun;86(6):523-5. doi: 10.1002/ajh.22020. Am J Hematol. 2011. PMID: 21594891 Free article. No abstract available.
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
Tarantini F, Cumbo C, Zagaria A, Parciante E, Anelli L, Coccaro N, Tota G, Minervini CF, Redavid I, Rossi AR, Conserva MR, Specchia G, Musto P, Albano F. Tarantini F, et al. Among authors: rossi ar. Hematology. 2022 Dec;27(1):842-846. doi: 10.1080/16078454.2022.2108902. Hematology. 2022. PMID: 35938951
76 results